Lucentis® (ranibizumab)

BL 125156

Lucentis® (ranibizumab)

BL 125156

U.S. License Holder:

Genentech

Date of License:

June-30-2006

Last Update:

January-23-2023

approved_indications FDA-Approved Indications


LUCENTIS (ranibizumab), a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:

Neovascular (Wet) Age-Related Macular Degeneration (AMD);

Macular Edema Following Retinal Vein Occlusion (RVO);

Diabetic Macular Edema (DME);

Diabetic Retinopathy (DR);

Myopic Choroidal Neovascularization (mCNV).

approved_indications aBLA / 505(b)(2) Activity


aBLA / 505(b)(2) Approved by FDA

Byooviz: Samsung Bioepis / Biogen (September-2021) Cimerli: Coherus / Bioeq (Interchangeable August-2022)

aBLA / 505(b)(2) Accepted by FDA

Xlucane: Xbrane (Withdrawn May-2022)

approved_indications Approved Foreign Follow-On Biologics / Biosimilars


Biosimilars Approved In Canada

Byooviz (Samsung Bioepis / Biogen) (March-2022)

Biosimilars Approved In The E.U.

Byooviz (Samsung Bioepis / Biogen) (August-2021)
Ongavia (Teva / Bioeq) (May-2022 in the United Kingdom)
Ranivisio (Teva / Bioeq) (August-2022)
Ximluci® (STADA / Xbrane) (November-2022 in the EU; January-2023 in the United Kingdom)

Biosimilars Approved In South Korea

Amelivu (Samsung Bioepis) (May-2022)
LucenBS (Chong Kun Dang) (October-2022)

approved_indications Inter Partes Review Proceedings

PTAB Portal

IPR Case No(s):

U.S. Patent No.
9,220,631 (Syringe)

Patent Owner
Novartis Pharma AG; Novartis Pharmaceuticals Corporation; Novartis Technology LLC

Petitioner(s)
Regeneron Pharmaceuticals, Inc.

§ 102 Challenge
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment Other

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted; Request for Rehearing Withdrawn

U.S. Patent No.
9,220,631 (Syringe)

Patent Owner
Novartis Pharma AG; Novartis Pharmaceuticals Corporation; Novartis Technology LLC

Petitioner(s)
Regeneron Pharmaceuticals, Inc.

§ 102 Challenge
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment Other

§ 103 Challenge Instituted
Terminated Prior to Institution Decision

Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Terminated Prior to Institution Decision at Petitioner's Request)

IPR Status
Terminated Prior to Institution Decision at Petitioner's Request

U.S. Patent No.
9,220,631 (Syringe)

Patent Owner
Novartis Pharma AG; Novartis Pharmaceuticals Corporation; Novartis Technology LLC

Petitioner(s)
Regeneron Pharmaceuticals, Inc.

§ 102 Challenge
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment Other

§ 103 Challenge Instituted
Awaiting Institution Decision

IPR Status
Awaiting Institution Decision

U.S. Patent No.
9,220,631 (Syringe)

Patent Owner
Novartis Pharma AG; Novartis Pharmaceuticals Corporation; Novartis Technology LLC

Petitioner(s)
Regeneron Pharmaceuticals, Inc.

§ 102 Challenge
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment Other

§ 103 Challenge Instituted
Y

Final Written Decision Issued
Y

Federal Circuit Appeal(s)
23-1334

IPR Status
Final Written Decision (All Challenged Claims Unpatentable); Federal Circuit Appeal Pending

approved_indications U.S. Patent Litigations

PACER

Case No(s):

U.S. Patent Nos.
5,688,688 (Vector for Expression of a Polypeptide in a Mammalian Cell)

Plaintiffs
Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Grifols Worldwide Operations Limited

Defendants
Regeneron Pharmaceuticals, Inc.

Status
Judgment of Non-Infringement and Order of Dismissal

BPCIA
N

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha